secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2023-09-22T23:59:59+00:00
Accession:  0001214659-23-012579
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro granted Nasdaq extension to Nov 15, 2023; must execute reverse stock split by Nov 1
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel grants extension until Nov 15, 2023 to regain $1.00 minimum bid compliance.
- Conditions: obtain stockholder approval for reverse stock split (ratio 1:2 to 1:20) by Sept 29, 2023.
- Company must effect reverse stock split by Nov 1, 2023 and then maintain $1.00 closing bid for 10 consecutive business days.
- Annual stockholder meeting scheduled for Sept 29, 2023 to approve reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923012579/0001214659-23-012579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923012579/z9212308k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-23-012579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer